Clene Nanomedicine, Inc.

#DYK? About 90% of people diagnosed with #ALS have no known family history of or genetic cause for this debilitating disease. Learn more from The ALS Association to increase your #ALSawareness: https://bit.ly/3e3BsCk

Neuronal energy deficits occur in neurodegenerative diseases like #ALS, resulting in neuronal dysfunction and death. Our nanotherapeutic #CNMAu8 supports energy production in neurons to help restore healthy neuron function. Learn more: https://bit.ly/3VrtSs0 #EndALS

#ICYMI: Earlier this month, Merit Cudkowicz, MD, MSc, Robert P. Bowser, Ph.D., and Clene Nanomedicine, Inc.’s Head of Medical Benjamin Greenberg, MD, MHS, FAAN, presented an update on the long-term data for #CNMAu8 in a Northeast ALS Consortium (NEALS) Meeting webinar moderated by Jinsy Andrews, MD, MSc, FAAN. In the webinar, the panel discussed emerging long-term evident of biomarker data, survival and ALS clinical worsening improvements in response to CNM-Au8 treatment. Watch it now: https://bit.ly/3YhTMhY

#ICYMI: Our very own Karen S. Ho, PhD, VP of Translational Medicine, shared her experience transitioning from academic to biotech research and spelled out Clene Nanomedicine, Inc.’s vision for treating neurodegenerative diseases with nanoparticle-based therapeutics. Check it out: https://bit.ly/3yeU6VM #EndALS #MSresearch #EmployeeSpotlight

Happy National Nanotechnology Day from Clene Nanomedicine, Inc.! Today, we celebrate the many improvements that #nanotechnology can make in our lives across a broad range of applications. Learn more about how we leverage #nano-therapeutics in our pipeline: https://bit.ly/3J9LcbH

#ALS KOLs Merit Cudkowicz, MD, MSC, and Robert P. Bowser, Ph.D., along with Clene Nanomedicine, Inc.’s Head of Medical, Benjamin Greenberg, MD, MHS, FAAN, will present an update on #CNMAu8 long-term data in a webinar on Wednesday, October 9, at 5:30 p.m. ET.   The panel, named “CNM-Au8 Long-term Data Update: Emerging Long-Term Evidence of Biomarker Data, Survival and ALS Clinical Worsening Improvements,” will be moderated by Jinsy Andrews, MD, MSc, FAAN.   Make sure you register: https://lnkd.in/e8DZDCZa

Clene Nanomedicine, Inc. is grateful to have received a fantastic metal print of the artwork depicting #CNMAu8’s neuroprotective action made for our cover issue of the top-tier nanoscience journal Small (Wiley) from Ella Maru Studio Inc. Thanks for the wonderful gift, Ella Marushchenko!

Clene Nanomedicine, Inc. announces closing of $7.3 million registered direct offering and concurrent private placements and amendment of debt facility. Read the full release here: https://bit.ly/47RGeOB

Clene Nanomedicine, Inc. announces $7.3 million registered direct offering and concurrent private placements priced at market under Nasdaq rules. Read the full release here: https://bit.ly/3zNaFcc

Clene Nanomedicine, Inc. CEO Rob Etherington recently shared his insights on the #biotech investment landscape with Russo Partners’ Conversations that Matter. Check it out!